FAQ
Intro
Survey
Topics
Please select the name from the list.
If the name is not there, means it is not connected with a GND -ID?

GND: 171428099


Click on a term to reduce result list Information symbol The result list below will be reduced to the selected search terms. The terms are generated from the titles, abstracts and STW thesaurus of publications by the respective author.

b

Match by:
Sort by:

The information on the author is retrieved from: Entity Facts (by DNB = German National Library data service), DBPedia and Wikidata

Alex M. Azar


Alternative spellings:
Alex Azar
Alex M. Azar II.

B: 1967 Johnstown, Pa.
The image of the author or topic
Source: Wikimedia Commons

Information about the license status of integrated media files (e.g. pictures or videos) can usually be called up by clicking on the Wikimedia Commons URL above.

Profession

  • Unternehmer
  • Politiker
  • External links

  • Gemeinsame Normdatei (GND) im Katalog der Deutschen Nationalbibliothek
  • Wikipedia (Deutsch)
  • Wikipedia (English)
  • NACO Authority File
  • Virtual International Authority File (VIAF)
  • Wikidata
  • International Standard Name Identifier (ISNI)


  • Twitter logo X (Twitter)

     

    Alex Michael Azar II (/ˈeɪzɑːr/; born June 17, 1967) is an American attorney, businessman, lobbyist, and former pharmaceutical executive who served as the United States Secretary of Health and Human Services from 2018 to 2021. Azar was nominated to his post by President Donald Trump on November 13, 2017, and confirmed by the United States Senate on January 24, 2018. He was also chairman of the White House Coronavirus Task Force from its inception in January 2020 to February 2020, when he was replaced by Vice President Mike Pence. Azar served as general counsel of the United States Department of Health and Human Services (HHS) from 2001 to 2005. On July 22, 2005, he was confirmed as the deputy secretary of Health and Human Services; he served in that capacity until his January 2007 resignation. From 2012 to 2017, Azar was president of the U.S. division of Eli Lilly and Company, a major drug company, and a member of the board of directors of the Biotechnology Innovation Organization, a large pharmaceutical trade association. In 2021, he was appointed a senior executive in residence at the Miami Herbert Business School at the University of Miami. (Source: DBPedia)

    Publishing years

    1
      1990

    Series